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ABSTRACT
Background. There is a lack of consensus regarding
optimal surgical excision margins for primary cutaneous
melanoma[ 1 mm in Breslow thickness (BT). A narrower
surgical margin is expected to be associated with lower
morbidity, improved quality of life (QoL), and reduced
cost. We report the results of a pilot international study
(MelMarT) comparing a 1 versus 2-cm surgical margin for
patients with primary melanoma[ 1 mm in BT.
Methods. This phase III, multicentre trial [NCT02385214]
administered by the Australia & New Zealand Medical
Trials Group (ANZMTG 03.12) randomised patients with a
primary cutaneous melanoma[ 1 mm in BT to a 1 versus
2-cm wide excision margin to be performed with sentinel
lymph node biopsy. Surgical closure technique was at the
discretion of the treating surgeon. Patients’ QoL was
measured (FACT-M questionnaire) at baseline, 3, 6, and
12 months after randomisation.
Results. Between January 2015 and June 2016, 400
patients were randomised from 17 centres in 5 countries. A
total of 377 patients were available for analysis. Primary
melanomas were located on the trunk (56.9%), extremities
(35.6%), and head and neck (7.4%). More patients in the
2-cm margin group required reconstruction (34.9 vs.
13.6%; p\ 0.0001). There was an increased wound
necrosis rate in the 2-cm arm (0.5 vs. 3.6%; p = 0.036).
After 12 months’ follow-up, no differences were noted in
QoL between groups.
Discussion. This pilot study demonstrates the feasibility of
a large international RCT to provide a definitive answer to
the optimal excision margin for patients with intermediate-
to high-risk primary cutaneous melanoma.
Following a diagnosis of primary cutaneous melanoma,
a secondary wider excision around the original biopsy scar
is advocated to reduce risk of local recurrence and improve
patient outcomes. Surprisingly, the extent of this elective
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wide excision is still to be resolved. Guidelines for surgical
margins of resection vary internationally, from 1 to 3 cm,
depending on Breslow thickness of the primary, which
translates into excision defects from 2 to 6 cm in diame-
ter.1–3 The recommended margins of excision for patients
with intermediate- and high-risk primaries is particularly
variable, with differing interpretations of the data from
two, similarly designed, randomised, controlled trials
(RCTs) fuelling the debate.4–8 The authors of one trial
concluded that a narrow, 1-cm margin resulted in increased
locoregional recurrence rate translating into a worse dis-
ease-specific survival and another group concluded that
there was no difference in either locoregional or disease-
specific survival with a narrow, 2-cm margin.4,5 There is a
growing concern internationally amongst surgeons that the
excess morbidity caused by larger excision defects,
including increased hospital stay, complications, and need
for reconstructive surgery, may not be necessary, particu-
larly because previous RCTs have shown that local
recurrence rates are low, ranging from 1.3% for interme-
diate-risk primaries to 3.3–4.3% for high-risk
primaries.5,9–11
With optimal therapy, approximately 90% of melanoma
patients survive beyond 10 years. Because the over-
whelming majority of melanoma patients have surgery and
no other treatment, quality of life after surgery is a key
survivorship issue. More than 110,000 patients are cur-
rently alive following a diagnosis of melanoma in the
United Kingdom.12 Long-term follow-up data of previous
RCTs have shown a significant worsening in quality-of-life
associated with postoperative morbidity and poor cosmesis
from surgical scars.9,13 A recent, multicentre, retrospective
analysis demonstrated that the prevalence of chronic,
moderate-severe neuropathic pain was 8% following wide
excision for melanoma.14
Currently, approximately 40% of all melanoma patients
with intermediate- to high-risk primaries are subject to 2-
to 3-cm excision margins. However, given the available
data, it is reasonable to suspect that a 1-cm margin may be
sufficient to achieve local control for over 95% of these
patients.5,9,11 The authors of the latest Cochrane review
concluded that an appropriately designed trial of an ade-
quate sample size is clearly needed to unify international
guidance and to benefit the large and increasing numbers of
melanoma patients worldwide.10 The purpose of the full
study will be to determine whether there is a difference in
local recurrence rates and melanoma survival rates for
patients treated with either a 1-cm excision margin or 2-cm
margin for both intermediate- and high-risk melanomas,
with survival outcomes, quality of life, and health eco-
nomics data as secondary measures. In this paper, we
present the feasibility data of the internal pilot study.
METHODS
MelMarT is a registered, phase III, surgical RCT [clin-
icaltrials.gov registration: NCT02385214] with
international ethical/IRB approval [Australian ethical reg-
istration number: HREC/14/RPAH/330] administered by
the Australia & New Zealand Medical Trials Group
(ANZMTG 03.12). Following diagnosis (by shave or
excision biopsy) of a primary cutaneous melanoma of
Breslow thickness[ 1 mm (pT2a-pT4b/AJCC IB-IIC;
AJCC 8th edition),15 eligible patients were randomised
electronically in a 1:1 fashion to either a 1 or a 2-cm wider
excision margin. In each arm, patients were staged at the
same operation with sentinel lymph node biopsy (SLNB).
Patients were stratified according to age, sex, and AJCC
stage (intermediate risk: IB-IIA and high risk: IIB-IIC).
Review of the primary melanoma histology slides was
performed internally at participating institutions by desig-
nated dermatopathologists. At the time of definitive
surgery, the designated margin was measured from the
scar, marked, and photographed for quality assurance. The
skin incision was continued vertically down through sub-
cutaneous tissue to the deep fascia, which could be
removed en bloc at the surgeon’s discretion. Patients
underwent direct primary closure or reconstructive surgery
with a local flap or a skin graft according to the preference
of the treating surgeon. Patients with positive SLNB were
managed according to the treating unit’s local protocol.
Patients’ quality of life was measured using the vali-
dated FACT-M questionnaire version 4 at baseline then 3,
6, and 12 months postrandomisation.16 Neuropathic pain
was measured at the same time points using the validated
PainDetect questionnaire.17 Health economics data (not
reported in this paper) were collected in prespecified cen-
tres using EQ 5-D questionnaire with patient-specific
financial questionnaires and health resource usage data.18
RESULTS
Between January 2015 and June 2016, 400 patients were
randomised in 17 centres across 5 countries. The database
was locked and analysed according to the predesignated
statistical plan once the last patient randomised had com-
pleted 12 months follow-up and completed their quality of
life data (June 2017). Figure 1 shows the CONSORT dia-
gram. Comprehensive screening data were available from
the majority of the recruiting centres (Fig. 1). In total, 1358
patients were screened of which 718 (52.9%) met the
inclusion criteria. Of these, 318 were not enrolled; 245
(77.0%) patients declined to be enrolled, 49 (15.4%)
patients were unable to undergo the treatment intervention
within the protocol-prescribed timeframe, 14 (4.4%)
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patients were not deemed suitable for the trial by the
clinician, and 10 (3.1%) patients declined the sentinel
lymph node biopsy procedure.
In this study, 377 patient datasets were available for
analysis (23 patients were deemed ineligible or withdrew
consent). Table 1 indicates the details of the patient
demographics and tumour characteristics. Both cohorts
were well-matched with no significant differences. The
majority of the lesions were located on the torso (56.9%),
followed by the extremities (35.6%) and the head and neck
region (7.4%). The rate of positive SLNB was 15.2% in the
1-cm group and 22.9% in the 2-cm group (absolute dif-
ference: 7.7%; p = 0.058).
Table 2 indicates the reconstructive burden across the
two cohorts; 34.9% patients required reconstruction with a
skin graft or local flap in the 2-cm group compared with
13.6% in the 1-cm group [p\ 0.0001; odds ratio (OR) 3.4
(2.0–5.8)]. There was a significantly increased need for
reconstruction in the 2-cm group at all locations, especially
the extremities and head and neck.
The quality of life data indicated no difference from
baseline at any time point for the majority of the FACT-M
subscales neither within nor between the randomisation
groups, nor on subgroup analysis. The exceptions were the
‘‘melanoma surgery’’ subscale, which showed a significant
and sustained decrease in score (indicating a worse quality
of life for this subscale) from baseline (p\ 0.0001 at 3, 6,
and 12 months with reference to baseline) and the ‘‘emo-
tional well-being’’ subscale, which showed a significant
and sustained increase in score (indicating an improved
quality of life for this subscale) from baseline (p\ 0.0001
at 3, 6, and 12 months with reference to baseline; Fig. 2a–
c). There was no difference between the 1 and 2-cm arms
in these two subscales. Neuropathic pain score analysis
indicated a significant but transient increase in pain level;
Assessed for eligibility n= 1358
Met inclusion criteria n= 718
Excluded: 318
Consent refused n= 245
Site delays n= 49
Clinician decision n= 14
Declined SLNB n= 10
Randomised
n = 400
1cm excision
n = 198
2cm excision
n = 202
High risk group
n = 37
High risk
group n = 42
Intermediate
risk group
n = 161
Intermediate
risk group
n = 160
Excluded: 4 Excluded: 9 Excluded: 3 Excluded: 7
Ineligible n=3
Withdrew consent n=1
Ineligible n=4
Withdrew consent n=5
Ineligible n=2
Withdrew consent n=1
Ineligible n=5
Withdrew consent n=2
Analysed
n= 33
Analysed
n= 152
Analysed
n= 39
Analysed
n= 153
FIG. 1 CONSORT diagram for MelMarT
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the strongest pain and highest average pain scores were
recorded at 3 months compared with baseline across both 1
and 2-cm groups. The scores returned to baseline at 6 and
12 months.
Table 3 outlines the perioperative surgical adverse
events data at the wide excision sites. The overall treat-
ment-related surgical adverse event rate was 10.3% in the
1-cm arm and 11.4% in the 2-cm arm (difference not sig-
nificant). There was a significant increase in wound
necrosis in the 2-cm arm compared with the 1-cm arm (3.6
vs. 0.5%, p = 0.036). With one exception (a haematoma in
the 2-cm arm; grade IIIa), the adverse events were minor or
mild: grade I–II in both the 1 and 2-cm arms. In follow-up,
the melanoma-related surgical adverse event rate was 5.4%
in the 1-cm arm and 3.6% in the 2-cm arm (difference not
significant).
DISCUSSION
In this study, we have presented the feasibility data and
initial quality of life outcomes data for the internal pilot
study for MelMarT, a large phase III RCT that requires a
TABLE 1 Patient and tumour characteristics
Patient characteristics 1 cm (n = 185) 2 cm (n = 192) Total (n = 377)
Gender
Male 104 (56.2%) 107 (55.7%) 211 (54.5%)
Female 81 (43.8%) 85 (44.3%) 186 (45.5%)
Age (year)
Mean (SD) 58.97 (± 13.10) 58.19 (± 13.21) 58.50 (± 13.15)
Age (year)
\ 45 28 (15.1%) 28 (14.6%) 56 (14.5%)
45–65 86 (46.5%) 89 (46.4%) 175 (45.2%)
[ 65 71 (38.4%) 75 (39.1%) 146 (40.3%)
BMI
Mean (SD) 28.43 (± 6.56) 28.38 (± 5.20) 28.40 (± 5.88)
ECOG score
0 173/181 (95.6%) 176/187 (94.1%) 349 (94.8%)
1 8/181 (4.4%) 11/187 (5.9%) 19 (5.2%)
Tumour characteristics 1 cm (n = 185) 2 cm (n = 192) Total (n = 377)
Breslow thickness (mm)
Mean (SD) 2.12 (± 1.17) 2.27 (± 1.39) 2.20 (± 1.28)
Min max 1.0, 7.5 1.0, 8.5 1.0, 8.5
Breslow thickness (mm)
1.0–2 111 (60.0%) 112 (58.3%) 223 (59.2%)
2.1–4 61 (33.0%) 60 (31.3%) 121 (32.1%)
[ 4 13 (7.0%) 20 (10.4%) 33 (8.7%)
Mitotic rate
Mean (SD) 4.81 (± 5.26) 4.88 (± 5.07) 4.84 (± 5.16)
Ulceration
Present 47 (25.4%) 52 (27.1%) 99 (26.3%)
Absent 138 (74.6%) 138 (71.9%) 276 (73.2%)
Unknown 0 (0.0%) 2 (1.0%) 2 (0.5%)
Location
Head and neck 12 (6.5%) 16 (8.9%) 28 (7.4%)
Axial 102 (55.4%) 112 (58.3%) 214 (56.9%)
Extremity 70 (38.0%) 64 (33.3%) 134 (35.6%)
Sentinel node status
Positive 28 (15.2%) 44 (22.9%) 72 (19.1%)
Negative 156 (84.8%) 148 (77.1%) 304 (89.9%)
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sample size of nearly 10,000 patients to test the coprimary
endpoints of local recurrence and melanoma-specific sur-
vival. A noninferiority statistical design is required to
prove parity in terms of safety and efficacy of the clinical
endpoints between the 1 and 2-cm arms, which, combined
with the relatively low event rate of the primary outcome
of local recurrence, inflates the sample size greatly com-
pared with a superiority design.19 Accordingly, before
embarking on this large endeavour, it was necessary to
conduct an internal pilot to test the robustness of the pro-
tocol and recruitment rates across multiple centres
internationally.
Unlike previous RCTs performed to assess margins, the
MelMarT study mandates SLNB as eligibility crite-
ria.5,9,11,20–22 This ensures optimal staging and risk
stratification. It was interesting to note that, despite careful
stratification according to patient and primary tumour
characteristics, the absolute difference in SLNB positivity
between the two cohorts was 7.7%, which was a near-
significant finding (p = 0.058). These data highlight and
lend weight to the concerns that have been raised regarding
the interpretation of the results of previous RCTs.4,7,11 In
particular, Hayes et al. proposed that the findings in their
long-term analysis, demonstrating a worse clinical out-
come, were linked directly to their previous finding of
increased locoregional recurrence associated with a nar-
rower 1-cm excision margin compared with a 3-cm
excision margin.4,11 However, in both surgical groups, the
incidence of nodal recurrence outweighed the incidence of
local recurrence by at least 5–1. An alternative explanation,
that the excess nodal disease in the narrow margin group
was indicative of poor prognostic disease before the
intervention, rather than resulting from the narrow margin
intervention itself, has been suggested.7,23
Clinical Outcomes
The trial management committee deemed that it was not
appropriate to present any outcomes data related to the
primary endpoints after 1 year of follow-up. The major
clinical finding was that there was a significant increase in
the use of reconstructive procedures between the two
cohorts (Table 2). Overall, the rate of reconstruction was
more than doubled in the 2-cm arm compared with the
1-cm arm (39.4 vs. 13.6%, respectively; p\ 0.0001). The
largest difference was seen in the head and neck region
(1 cm: 8.3% vs. 2 cm: 68.8%; p = 0.002), although the
subgroup sample size was small and the confidence inter-
vals (CI) were wide; thus, the size of the difference needs
to be interpreted with caution. Similarly, there was a large
and significant difference in the incidence of reconstruction
in the extremities. Clinically, these data are relevant, given
the relative lack of tissue laxity in the extremities, the
cosmetic implications of large excision margins in the head
and neck region and the unique functional and anatomical
considerations of both areas. It is interesting to note that
only one prior RCT included patients with head and neck
cutaneous melanoma, comprising only 0.3% (16/326) of
cases in that particular study and\ 0.02% of all partici-
pants in the pooled RCT evidence to date.22 Two of the
previous RCTs reported a significantly increased need for
reconstruction when comparing a 2-cm wider excision
margin with a 4-cm margin. In the Scandinavian study, it
was possible to close the wound directly in 69% of the
2-cm group, which is close to our findings (65.1%).5 In the
Intergroup and the MSLT-1 studies, the overall recon-
struction rates were 28 and 22% respectively, again similar
to our own data.9,24 Haigh et al. performed a systematic
review of all the available data at the time and estimated
TABLE 2 Reconstruction rates by cohort and anatomical location
Reconstruction? (Y/N) 1 cm (n = 184) 2 cm (n = 192) Total (n = 376) Significance
Any site
Yes 25 (13.6%) 67 (34.9%) 92 (24.5%) p\ 0.0001
OR 3.4 [2.0–5.8]No 159 (86.4%) 125 (65.1%) 284 (75.5%)
By primary location
Head and neck
Yes 1 (8.3%) 11 (68.8%) 12 (42.9%) p = 0.002
OR 19.3 [2.6–566.3]No 11 (92.6%) 5 (31.2%) 16 (57.1%)
Axial
Yes 15 (14.7%) 29 (25.9%) 44 (20.6%) p = 0.043
OR 2.0 [1.0–4.1]No 87 (85.3%) 83 (74.1%) 170 (79.4%)
Extremity
Yes 9 (12.9%) 27 (42.2%) 36 (26.9%) p = 0.0003
OR 4.8 [2.1–12.1]No 61 (87.1%) 37 (57.8%) 98 (73.1%)
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that the number needed to harm from a wider excision was
3 (95% CIs 2.38–3.7), indicating that for every three
patients undergoing a wider excision, one patient would
undergo a reconstruction who would otherwise not require
it if a narrower margin had been used.25 In our dataset, the
number needed to harm was calculated as 4.69
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(95% CIs 3.45–8.1), indicating a substantial reconstructive
burden that could be avoided with the use of a narrower
1-cm margin compared to a 2-cm margin.
Quality of Life Outcomes
Our QOL data yielded interesting and possibly surpris-
ing results. Ultimately there was no difference in quality of
life or neuropathic pain data in any domain between the 1
and 2-cm groups. Similarly, there were no differences
between the two margins in any subgroup analyses. One
RCT QOL analysis was published from the UK BAPS/
MSG study comparing 1 versus 3-cm margins for thicker
melanoma.13 The wider margin was associated with a
worse QOL initially, which normalised to baseline after
6 months. This was the case for both the mental and
physical component scores of QOL tool employed. In our
study, we noticed a significant worsening of the FACT-M
melanoma surgery subscale, which persisted after
12 months (Fig. 2). Similarly, the emotional well-being
subscale progressively improved over the 12-month post-
operative period. The differences between our study and
the U.K. BAPS/MSG study may be due to the different
QOL tools used, although the improvement in emotional
well-being may be representative of the improved multi-
disciplinary care and support most patients currently
receive in major cancer centres.
Adverse Events
We found that the surgical adverse event rate (AER) was
nearly identical for both arms of the study: approximately
10–11%. The complication rate was the same between the
two arms of the study except the wound necrosis/skin graft
loss rate. We suggest that this is related to the increased
rate of reconstruction in the 2-cm arm. The wide excision
biopsy site surgical AER was 5.4 and 3.6% in the 1 and
2-cm groups, respectively. In comparison, the Intergroup
trial demonstrated an approximate 5% complication rate at
the primary site, regardless of margin.9 The Sunbelt Mel-
anoma Trial demonstrated a 4.6% surgical AER at the
sentinel node biopsy site, which is comparable to our
data.26 Nearly all surgical AEs recorded in our study were
grade I or II indicating that the procedures were performed
to a uniformly high standard in the recruiting centres.
Recruitment
Our data indicate that the pilot study had a high rate of
recruitment with the majority of potentially eligible
patients declining participation rather than not being
offered the trial. These are encouraging data and are likely
to be due to both the permissive trial design, allowing
patients to be recruited to subsequent trials upon progres-
sion or discovery of a positive sentinel node biopsy, and the
relative lack of competing clinical trials for patients who
are at the same stage of the disease. Furthermore, the
successful completion of the pilot study indicates enthusi-
astic engagement by clinicians and consumer groups
internationally who are keen to see the issue resolved for
the benefit of future patients. A simple trial design with the
experimental intervention representing a seemingly modest
modification of the internationally accepted standard of
care also lends itself greatly to successful recruitment.
TABLE 3 Surgical adverse events at wide excision site
Surgical adverse event (Clavien-Dindo grade) 1 cm n (events) % 2 cm n (events) %
Wound dehiscence 4 2.2 4 3.2
Haematoma 3 1.6 2 1
Grade I 3 1.6 1 0.5
Grade IIIa 0 1 0.5
Haemorrhage 0 0
Wound infection 11 5.9 9 4.7
Grade I 1 0.5 3 1.6
Grade II 10 5.4 6 3.1
Wound necrosis (including partial/total loss of skin graft) 1 0.5 7 3.6*
Grade I 0 6 3.1
Grade II 1 0.5 1 0.5
Total 19 10.3 22 11.4
*p = 0.036
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CONCLUSIONS
We have shown that the MelMarT study design is fea-
sible and straightforward to recruit to and implement.
Prospective, future patients and clinicians would benefit
from this information in the preoperative consultation to
aid undertaking informed consent. The rate of reconstruc-
tion is significantly increased when a wider margin is
employed, and this is consistent with previous RCTs. This
information that can be used immediately in clinical
decision-making, particularly where local recurrence rates
are very low, namely the pT2 subgroup of patients. In
summary, the internal pilot of MelMarT has been suc-
cessful, indicating that the international phase III trial
should proceed with only minor amendments to the
protocol.
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